PGPriti Gros

Priti Gros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priti Gros has a total of 59 co-authors. Here are the top co-authors by number of shared publications:

  • Aleksandar Videnovic

    Movement Disorders Unit, Division of Sleep Medicine, Massachusetts General Hospital, Harvard Medical School, Neurological Clinical Research Institute, 165 Cambridge Street, Suite 600, Boston, MA 02114, USA

    2 shared publications
  • Connie Marras

    ICES

    2 shared publications
  • Jun Guan

    ICES

    2 shared publications
  • Xuesong Wang

    ICES Toronto Ontario Canada

    2 shared publications
  • A. Benedetti

    Respiratory & Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; Department of Biostatistics, Faculty of Medicine, McGill University, Montreal, QC, Canada

    1 shared publication
  • A. Robinson

    Respiratory & Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    1 shared publication

Latest Publications

  • Open Access

    Virtual Care Trends in Older Adults with Parkinson’s Disease in Urban and Rural Ontario, Canada, During COVID-19

    by Priti Gros, Tomi Odugbemi, Laura Maclagan, Zhiyin Li, Jun Guan, Connie Marras, Anthony Lang, Lorraine Kalia, Richard H. Swartz, Susan E. Bronskill

    Background: Virtual care services increased during the COVID-19 pandemic, enabling access to physician consultations. Most studies on virtual care in Parkinson’s disease (PD) have focused on tertiary centers, limiting generalizability. Objective: To describe trends in virtual care use over time in people living with PD in Ontario, Canada, by rural and urban region of residence using health administrative data. Methods: We conducted a population-based repeated cross-sectional study between March 2020 and August 2023, among community-dwelling people living with PD aged ≥66 years in Ontario, Canada. We used Poisson regression models with generalized estimating equations to estimate rate ratios (RR) with 95% confidence intervals (CIs) comparing virtual visit rates in urban versus rural areas across physician specialties (family physicians, neurologists and psychiatrists/geriatricians). Results: Among 24,736 people living with PD in March 2020, 58.6% were male (mean age 77.6 [SD = 7.0] years), and most resided in urban areas (89.9%). Compared to urban residents, rural residents had significantly lower rates of virtual visits to neurologists (adjusted RR = 0.93; 95% CI: 0.90–0.96), family physicians (aRR = 0.73; 95% CI: 0.70–0.77) and geriatricians/psychiatrists (aRR = 0.67; 95% CI: 0.65–0.77). Over 3.5 years, virtual visits declined compared to the first 6 months for neurologists (aRR = 0.23; 95% CI: 0.22–0.25), family physicians (aRR = 0.39; 95% CI: 0.38–0.41) and geriatricians/psychiatrists (aRR = 0.45; 95% CI: 0.40–0.51). Conclusion: People living with PD in urban centers accessed virtual care more frequently than those living rurally. Virtual care utilization decreased over time. The sustainability of virtual care and its impact on health equity among people living with PD requires further study.

  • Sleep Medicine Resource Utilization in Individuals With Parkinson Disease

    by Ryan Gotfrit, Robert Talarico, Priti Gros, Marta Kaminska, Tiago A. Mestre, Tetyana Kendzerska

    Individuals with Parkinson disease (PD) may face barriers in obstructive sleep apnea diagnosis/management due to sleep being lower priority and sleep disturbances being poorly recognized. Evidence on sleep-medicine service utilization in the PD population is lacking. We conducted a population-based study to identify discrepancies in sleep-medicine resource use (prevalence rates of polysomnograms [PSG] performed and positive airway pressure [PAP] initiated) over a 10-year period between the PD population and the matched non-PD population. We conducted a retrospective longitudinal population-based study using health administrative databases in Ontario from 2012 to 2021 in adults with PD to compare overall and annual prevalence rates of PSGs performed and PAP initiated to 1:1 randomly selected propensity score matched controls from the matched non-PD population based on simultaneous exact matching on age, sex, and calendar year and caliper matched propensity scores from a logistic regression model (based on sociodemographic variables and comorbidities) using validated health administrative definitions to identify PD cases and controls. We hypothesized that the PD population has lower rates of PSGs performed and PAP treatments initiated compared with the similar matched non-PD population. We used Poisson regression to estimate annual prevalence rate ratios to determine the relative change in prevalence over the study period between the groups. Sixty-five thousand, one hundred sixty-seven patients with PD and 11,460,672 controls met our inclusion criteria. We successfully propensity score matched 64,879 PD cases to controls. From 2012 to 2021, there were a higher prevalence of any PSG performed in the PD population (8.2% vs 6.3%, [RR: 1.30, 95% CI: 1.25-1.35], p < 0.001) and no difference in the rates of any PAP initiated in the PD population vs controls (4.0% vs 4.1%, [RR: 0.93-1.03, 95% CI: 0.93-1.03], p = 0.46). For both groups, annual prevalence rates generally increased over time. There was no difference in the annual prevalence rate ratio of any PSG performed or any PAP initiated in the PD population vs controls (1.07 [95% CI: 1.06-1.07] vs 1.07 [95% CI: 1.07-1.08], p = 0.5; 1.10 [95% CI: 1.09-1.11] vs 1.11 [95% CI: 1.10-1.11], p = 0.18, respectively). Sleep-medicine resource utilization in the PD population is at least similar to the matched non-PD population and follows the increase with time observed in the general population.


  • Teaching NeuroImage: Clinicoradiologic Clues in Aceruloplasminemia

    by Nikolai Gil D. Reyes, Priti Gros, Paula Alcaide-Leon, Anthony E. Lang, Gabor G. Kovacs

  • Motor fluctuations in Parkinson disease – a mini-review of emerging drugs

    by Priti Gros, Laura Armengou Garcia, Susan H. Fox

    The symptomatic treatment of Parkinson Disease (PD) relies on levodopa. With disease progression, the response to levodopa becomes variable, leading to fluctuations in benefit on PD symptoms. These motor fluctuations are challenging to manage and negatively impact quality of life in PD. We provide a review of experimental, non-approved pharmacological therapies in phase II and III clinical trials from 2018 to 2024 for PD motor fluctuations. New formulations of levodopa to improve bioavailability are in development. These include another subcutaneous infusion with efficacy in reducing motor fluctuations and an intranasal delivery with tolerability reported. An oromucosal formulation of apomorphine was safe, further studies are needed. Preliminary results of a phase III study of dopamine D1/D5 agonist tavapadon and phase II of CVN424, a GRP6 inverse agonist suggest improved ON time. Negative studies were reported with foliglurax (MGluR4 inverse agonist) and the repurposed drugs naftazone and bumetanide. Several novel targets are in early-stage development with results awaited. Overall, it is unclear whether the field is significantly further ahead, as the benefit of these emerging drugs in comparison with currently available agents for motor fluctuations needs to be clarified.


  • Open Access

    Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials

    by Priti Gros, Connie Marras, Xuesong Wang, Maria Chiu, Michael E. Farkouh, Abby Emdin, Susan E. Bronskill

    Background: Parkinson disease (PD) disease‐modifying therapy (DMT) trials generally recruit individuals from teaching hospitals. Whether these participants represent the broader PD population is unclear.Objective: The objective was to compare individuals with PD seen by neurologists in teaching hospitals early in their disease—a proxy for DMT trial‐eligible cohorts—with individuals seen in other settings.Methods: This retrospective cohort study using population‐based data from Ontario (Canada) included individuals with PD from 1995 to 2017. Individuals with ≥1 PD visit with a teaching hospital neurologist within 3 years served as a proxy for DMT trial‐eligible participants. Comparators were individuals with PD seen in other settings. We compared age, sex, income, rurality, marginalization, and comorbidities. We measured time to milestones, including drug escalation, surgical/infusion therapies, home care, dementia, long‐term care admission, and death.Results: We identified 19,948 individuals with PD, of whom 4386 (22.0%) were seen by a teaching hospital neurologist and 15,562 (78.0%) in other settings. Compared to other settings, individuals with teaching hospital neurology visits were younger, belonged to socioeconomically advantaged neighborhoods, and had fewer comorbidities. They had more drug escalation (unadjusted hazard ratio = 1.30; 95% confidence interval [CI] = (1.21, 1.38), surgical or infusion therapies (2.35 [2.09, 2.64]), and home care (1.06 [1.02, 1.10]). They had less dementia (0.813 [0.77, 0.86]), long‐term care admission (0.62 [0.58, 0.67]), and death (0.68 [0.64, 0.72]).Conclusions: Individuals with PD seen early by teaching hospital neurologists exhibited differences from the PD population. DMT trials in PD may exclude individuals with faster PD progression and from marginalized groups, impacting generalizability. Our study highlights health equity issues. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Experimental Therapeutics in Parkinson’s Disease

    by Priti Gros, Laura Armengou Garcia, Susan H. Fox


  • Open Access

    Rehabilitation for Functional Dystonia: Cases and Review of the Literature

    by Priti Gros, Haseel Bhatt, Gabriela S. Gilmour, Sarah C. Lidstone

    Background: Functional dystonia (FD) is a common subtype of functional movement disorder. FD can be readily diagnosed based on positive signs and is potentially treatable with rehabilitation. Despite this, clinical outcomes remain variable and a gold standard approach to treatment is lacking.Cases: Here we present four cases of axial and limb functional dystonia who were treated with integrated rehabilitation and improved. The therapy approach and clinical outcomes are described, including videos.Literature review: A literature review evaluated the published treatment strategies for the treatment of functional dystonia. Out of 338 articles, 25 were eligible for review and included mainly case reports and case series. Most patients received more than one treatment modality. Non‐invasive therapies, commonly physiotherapy and psychological approaches were mostly associated with positive outcomes. Multiple treatments commonly used in dystonia were used, including botulinum toxin injections, pharmacotherapy and surgery, leading to variable outcomes.Conclusion: Therapy should be personalized to the clinical presentation. In challenging cases, initiation of a multidisciplinary approach may provide benefit regardless of etiology. Pharmacotherapy should be used judiciously, and surgical therapy should be avoided.


  • Prevention and treatment of traumatic brain injury-related delirium: a systematic review

    by Yu Qing Huang, Sophie Weiss, Priti Gros, Edwin Wong, Pierre-Philippe Piché, Manav V. Vyas, Alan Ka Ho Tam, Jennifer Ann Watt

    Background Our systematic review examines the effectiveness and safety of non-pharmacologic and pharmacologic interventions in preventing or treating traumatic brain injury (TBI)-related delirium in acute care. Methods We searched four electronic databases (MEDLINE, EMBASE, CENTRAL/CDSR, and PsycINFO) to identify randomized controlled trials (RCTs), quasi-experimental, and observational studies. Eligible studies included adults with TBI, at least one comparator group, delirium as an outcome and took place in acute care. Two reviewers independently completed all study screening, data abstraction, and risk of bias assessment using the Cochrane risk of bias 2 tool for RCTs or risk of bias in non-randomized studies—of interventions tool for observational studies. We implemented the PROGRESS-Plus framework to describe social determinants of health (SDoH) reporting. Results We identified 20,022 citations, reviewed 301 in full text, and included eight studies in the descriptive synthesis. The mean age of study participants ranged from 32 to 62 years. 12.5% of included studies reported SDoH. Included studies had moderate-to-high risk of bias. Studies compared reorientation programs and an intervention bundle to usual care, but these interventions were not better than usual care in treating TBI-related delirium. Individual studies found that rosuvastatin and aripiprazole were more efficacious than placebo, and dexmedetomidine was more efficacious than propofol and haloperidol for preventing TBI-related delirium. No studies reported safety as the primary outcome. Conclusions We identified efficacious pharmacologic interventions for preventing TBI-related delirium, but these studies were at moderate-to-high risk of bias, which limits our confidence in these findings. Future studies should incorporate safety outcomes, and a diverse study population, including older adults.


  • Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD)

    by M. Kaminska, M. O'SUllivan, V.P. Mery, A.L. Lafontaine, A. Robinson, P. Gros, J.G. Martin, A. Benedetti, R.J. Kimoff


  • Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease

    by Priti Gros, Xuesong Wang, Jun Guan, Anthony E. Lang, Peter C. Austin, Blayne Welk, Naomi P. Visanji, Connie Marras

    Background: Preclinical and epidemiological data suggest that phosphoglycerate kinase 1 activators could have neuroprotective properties and prevent PD.Objectives: The objective of this study was to compare the association between increased use of phosphoglycerate kinase 1 activators and increased use of tamsulosin with PD incidence.Methods: Our retrospective cohort study included men older than age 66 years newly exposed to phosphoglycerate kinase 1 activators or tamsulosin and compared their PD incidence, using health care administrative data of Ontario, Canada.Results: Among 265,745 men, each additional year of cumulative use of phosphoglycerate kinase 1 activators or tamsulosin was associated with 6% and 8% reduction, respectively, in the hazard of PD incidence. These hazards were not significantly different (P = 0.2094). A secondary analysis with the observation window starting after 6 months and 1 and 2 years showed similar results.Conclusions: Increasing exposure to phosphoglycerate kinase 1 activators and tamsulosin were both associated with small reductions in PD incidence. These results support further investigation of phosphoglycerate kinase 1 activators and tamsulosin for possible PD disease‐modifying properties. © 2021 International Parkinson and Movement Disorder Society